PIN17 Pharmacoeconomics of Cervarix Vaccines Against Human Papilloma Virus in the Republic of Kazakhstan

Simple item page
dc.contributor.authorNurgozhin, T.
dc.contributor.authorGulyaev, A.
dc.contributor.authorYermekbayeva, B.
dc.contributor.authorKushugulova, A.
dc.contributor.authorAkhmetova, A.
dc.contributor.authorSupiev, A.
dc.creatorT., Nurgozhin
dc.date.accessioned2017-12-13T08:50:51Z
dc.date.available2017-12-13T08:50:51Z
dc.date.issued2013-11-01
dc.identifierDOI:10.1016/j.jval.2013.08.2208
dc.identifier.citationT. Nurgozhin, A. Gulyaev, B. Yermekbayeva, A. Kushugulova, A. Akhmetova, A. Supiev, PIN17 - Pharmacoeconomics of Cervarix Vaccines Against Human Papilloma Virus in the Republic of Kazakhstan, In Value in Health, Volume 16, Issue 7, 2013, Pages A714-A715
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S109830151304120X
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2870
dc.relation.ispartofValue in Health
dc.rights.licenseCopyright © 2013 Published by Elsevier Inc.
dc.titlePIN17 Pharmacoeconomics of Cervarix Vaccines Against Human Papilloma Virus in the Republic of Kazakhstan
dc.typeArticle
dcterms.abstractBased on the pharmacoeconomic analysis determine the feasibility of vaccine against HPV-associated diseases in Kazakhstan.
elsevier.aggregationtypeJournal
elsevier.coverdate2013-11-01
elsevier.coverdisplaydateNovember 2013
elsevier.endingpageA715
elsevier.identifier.doi10.1016/j.jval.2013.08.2208
elsevier.identifier.eid1-s2.0-S109830151304120X
elsevier.identifier.piiS1098-3015(13)04120-X
elsevier.issue.identifier7
elsevier.issue.nameISPOR 16th Annual European Congress and 4th Latin America Conference Research Abstracts
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA714
elsevier.volume16

Files

Collections

Center for Life Sciences